Unicycive Therapeutics has hit a bump on the road in its mission to bring its hyperphosphatemia treatment candidate to ...

In the United States alone, about 1 in 10 adults use these drugs regularly. Some well-known brands include Prilosec, Nexium, ...

FDA issues a complete response letter for oxylanthanum carbonate, a treatment for hyperphosphatemia in patients with chronic ...

FDA denies Unicycive's NDA for Oxylanthanum Carbonate due to vendor issues; company eyes quick resolution with alternate ...

Ardelyx's IBSRELA shows strong 57% sales growth, but faces stiff competition and uncertain sustainability. Click here to read ...

Unicycive, which was seeking approval of oxylanthanum carbonate to treat hyperphosphatemia in patients with chronic kidney disease on dialysis, said the FDA issued a so-called complete response letter ...

Under a two-year contract, 150 of FME's 5008S CorDiax systems will be installed across participating renal treatment centres ...

When faced with the myriad diseases and equally numerous targets for potential drugs the company could pursue, Kewalramani ...

Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver ...

The intensity of CKD-aP is linked to levels of systemic inflammation, with reductions in these levels seen with difelikefalin treatment.

The FDA has approved a 200 mg/mL autoinjector of belimumab (Benlysta) for at-home subcutaneous use in children aged 5 years ...

Phosphate binders are often prescribed with meals for people with kidney disease to reduce the uptake of phosphate in food.